Clinical Oncology
Volume 20, Issue 6 , Pages 479-487, August 2008

Survivorship, Late Effects and Cancer of the Cervix

  • E.J. Maher

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: E. J. Maher, Mount Vernon Cancer Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK. Tel: +44-1923-844681.
  • ,
  • A. Denton

Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, UK

Received 21 February 2008; received in revised form 10 April 2008; accepted 29 April 2008.

Abstract 

As the prevention and treatment of cervical cancer improves, there is increasing focus on the months and years after cancer treatment. Of those women living after a diagnosis of cancer, 10% will have a gynaecological malignancy and although the incidence of cervix cancer has dropped over the last 20 years, so has the age at diagnosis, with more than 60% surviving at least 5 years. In a recent report, 63% of 231 064 US survivors of cervix cancer were more than 10 years from diagnosis. More survivors are living long enough to develop chronic treatment-related conditions. The 2007 English Cancer Reform Strategy highlighted the importance of cancer survivorship and uses the US National Coalition for Cancer Survivorship definition—‘living through and beyond cancer’. The emerging picture is of populations living after a diagnosis of cancer without active disease, still having similar health and disability profiles to populations with a diagnosis of a chronic illness. This offers new challenges in identifying and meeting their needs.

Key words: Cervix cancer, follow-up, late effects, pelvic radiotherapy, survivorship

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(08)00213-6

doi:10.1016/j.clon.2008.04.009

Clinical Oncology
Volume 20, Issue 6 , Pages 479-487, August 2008